Table 2. Effectiveness of BNT162b2 and mRNA-1273 Booster Vaccination against Infection with the Omicron Variant.
| Epidemiologic Measure | BNT162b2 Vaccine | mRNA-1273 Vaccine | ||
|---|---|---|---|---|
| Estimate | Effectiveness of Booster vs. Two-Dose Series (95% CI) |
Estimate | Effectiveness of Booster vs. Two-Dose Series (95% CI) |
|
| percent | percent | |||
| Total follow-up time — person-wk | ||||
| Booster cohort | 625,033 | — | 185,850 | — |
| Nonbooster cohort | 600,539 | — | 182,986 | — |
| Incidence rate of symptomatic infection per 10,000 person-wk (95% CI) | ||||
| Booster cohort | 49.0 (47.3–50.7) | — | 23.9 (21.8–26.2) | — |
| Nonbooster cohort | 92.9 (90.5–95.4) | — | 42.4 (39.5–45.5) | — |
| Adjusted hazard ratio for symptomatic infection (95% CI)* | 0.51 (0.48–0.53) | 49.4 (47.1–51.6) | 0.53 (0.47–0.59) | 47.3 (40.7–53.3) |
| Adjusted hazard ratio for Covid-19–related hospitalization and death (95% CI)† | 0.23 (0.12–0.44) | 76.5 (55.9–87.5) | — | — |
*
Cox proportional-hazards regression models were used to adjust for sex, 10-year age group, 10 nationality groups, and calendar week of the second-dose vaccination.
†
No estimate could be derived for the mRNA-1273 vaccine because there were no events in the booster cohort and few events in the nonbooster cohort.